Stabilization notice

Carnegie Investment Bank AB (”Carnegie”) notifies that stabilization measures have been undertaken in BioArctic AB (publ)’s (“BioArctic” or the “Company”) B-shares traded on Nasdaq Stockholm.

As announced in connection with the offering to acquire newly issued B-shares in the Company and the listing of the Company’s B-shares on Nasdaq Stockholm (the ”Offering”), Carnegie, acting as Global Coordinator, carries out transactions aimed at supporting the market price of the B-shares at levels above those which might otherwise prevail in the open market.

Stabilization transactions may be undertaken on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the date of commencement of trading in the B-shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter. Carnegie is, however, not required to undertake any stabilization and there is no assurance that stabilization will be undertaken. Stabilization, if undertaken, may be discontinued at any time without prior notice. In no event will transactions be effected at levels above the price in the Offering.

A few existing shareholders (“Selling Shareholders”) have granted Carnegie an over-allotment option, which may be utilized in whole or in part for 30 days from the first date of trading in the Company’s B-shares on Nasdaq Stockholm, to issue up to 4,375,000 additional B-shares, corresponding to up to 15 percent of the total number of B-shares encompassed by the Offering, at a price corresponding to the price in the Offering, i.e. SEK 24, to cover any over-allotment in connection with the Offering.

Carnegie has, in its capacity as stabilization manager, notified that stabilization measures have been undertaken, in accordance with article 5(4) in the Market Abuse Regulation 596/2014, on Nasdaq Stockholm as specified below. The contact person at Carnegie is Anna Boqvist (tel: +46 8 588 688 00).

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on October 20, at 05:45 p.m. CET.

For further information, please contact:

Gunilla Osswald, CEO at BioArctic
Email: gunilla.osswald@bioarctic.se
Telephone: + 46 (0)8 695 69 30

Christina Astrén Eriksson, Head of Communications at BioArctic
Email: christina.astren@bioarctic.se
Telephone: + 46 (0)70 835 43 36

Important information

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by BioArctic AB.

Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.

The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.